Phosphatase and tensin homolog (PTEN) is a key redox-sensitive tumour suppressor that antagonizes the PI3K-Akt cell signalling pathway and limits cell proliferation. Dysregulation of this pathway plays a role in breast cancers and in metabolic diseases. There is a strong link between inflammation, which causes oxidative stress, and cancer progression, but the mechanisms involved are not well understood. PTEN also affects other pathways through its protein phosphatase activity. This project will build on work at Aston using liquid chromatography tandem mass spectrometry to show that PTEN is covalently modified by reactive lipid oxidation products (a process called lipoxidation) produced during oxidative stress, which affects PTEN activity, localization and Akt activation. The aim of the project is to understand which cellular mechanisms contribute to deleterious cellular outcomes and identify the specific downstream signalling processes that are differentially affected in tumorigenic and non-tumorigenic breast epithelial cells.
Objectives:
- To determine the effect of oxidized lipid products on Akt, mTORC and GSK3 activation in tumorigenic (MCF-7) and non-tumorigenic (MCF-10A) cells using western blotting. qRT-PCR will be used to monitor PTEN and AKT transcript levels.
- To determine the effect of PTEN signalling on mitochondrial bioenergetics, mitochondrial dynamics and mitophagy in MCF-7 and MCF-10A using real-time oxygen consumption measurements and western blotting.
- To identify specific modifications of PTEN and its protein-protein interactions in MCF-7 and MCF-10A cells under inflammatory or stress conditions, using LC-MSMS approaches.
- To correlate changes in PTEN interactions and signalling with cellular outcomes (e.g. cellular proliferation, migration and invasion).
Together, this will provide detailed information on the contribution of redox stress and lipid oxidation to altered cell signalling and metabolism in tumour cells.